Evaluation of the CCL17/CCL22-CCR4 axis in pediatrics with B-cell acute lymphoblastic leukemia before and after a chemotherapy course

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Cytokine Pub Date : 2024-08-05 DOI:10.1016/j.cyto.2024.156721

Marzieh Motaghi , Abdollah Jafarzadeh , Alireza Farsinejad , Aida Norouzi , Hossein Khorramdelazad , Zahra Farahmandinia , Ali Afgar , Gholamhossein Hassanshahia

{"title":"Evaluation of the CCL17/CCL22-CCR4 axis in pediatrics with B-cell acute lymphoblastic leukemia before and after a chemotherapy course","authors":"Marzieh Motaghi , Abdollah Jafarzadeh , Alireza Farsinejad , Aida Norouzi , Hossein Khorramdelazad , Zahra Farahmandinia , Ali Afgar , Gholamhossein Hassanshahia","doi":"10.1016/j.cyto.2024.156721","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>Acute lymphoblastic leukemia (ALL) is the most common type of pediatrics cancer. Chemokines exert different roles in leukemia process through leukocyte recruitment and regulation of disease severity. Due to the prominent roles of chemokine/receptor axes, this study aimed to measure the blood expression levels of CCR4 and their ligands in pediatrics with B-cell ALL (B-ALL). We also evaluated the impact of cytotoxic chemotherapy on this axis.</p></div><div><h3>Material and Method</h3><p>Thirty children suffering from B-ALL were included in the study and followed up for 30 days after completion of a chemotherapy course. The blood sampling was performed before and after chemotherapy. 30 healthy donors have also entered the study as control subjects. The mRNA expression of CCL17, CCL22 and CCR4 genes was determined by quantitative real-time PCR. The frequency of the peripheral blood mononuclear cells expressing CCR4 (CCR4 + PBMCs) was also evaluated by the flow cytometry method. Moreover, we evaluated the association of the CCL17/CCL22-CCR4 axis with some diagnostic, prognostic and predictive biomarkers in ALL patients.</p></div><div><h3>Results</h3><p>There was overexpression of the CCL17/CCL22-CCR4 axis along with lactate dehydrogenase (LDH) in pediatrics with B-ALL compared to healthy controls. After induction of chemotherapy, the blood expression levels of the CCL17/CCL22-CCR4 axis have reached the levels of healthy controls. The findings for the blood expression levels of CCR4 were also confirmed using flow cytometry.</p></div><div><h3>Conclusion</h3><p>The CCL17/CCL22-CCR4 axis can be used as a novel predictive and prognostic biomarker in B-ALL.</p></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"182 ","pages":"Article 156721"},"PeriodicalIF":3.7000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624002242","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

Acute lymphoblastic leukemia (ALL) is the most common type of pediatrics cancer. Chemokines exert different roles in leukemia process through leukocyte recruitment and regulation of disease severity. Due to the prominent roles of chemokine/receptor axes, this study aimed to measure the blood expression levels of CCR4 and their ligands in pediatrics with B-cell ALL (B-ALL). We also evaluated the impact of cytotoxic chemotherapy on this axis.

Material and Method

Thirty children suffering from B-ALL were included in the study and followed up for 30 days after completion of a chemotherapy course. The blood sampling was performed before and after chemotherapy. 30 healthy donors have also entered the study as control subjects. The mRNA expression of CCL17, CCL22 and CCR4 genes was determined by quantitative real-time PCR. The frequency of the peripheral blood mononuclear cells expressing CCR4 (CCR4 + PBMCs) was also evaluated by the flow cytometry method. Moreover, we evaluated the association of the CCL17/CCL22-CCR4 axis with some diagnostic, prognostic and predictive biomarkers in ALL patients.

Results

There was overexpression of the CCL17/CCL22-CCR4 axis along with lactate dehydrogenase (LDH) in pediatrics with B-ALL compared to healthy controls. After induction of chemotherapy, the blood expression levels of the CCL17/CCL22-CCR4 axis have reached the levels of healthy controls. The findings for the blood expression levels of CCR4 were also confirmed using flow cytometry.

Conclusion

The CCL17/CCL22-CCR4 axis can be used as a novel predictive and prognostic biomarker in B-ALL.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

化疗前后对儿童 B 细胞急性淋巴细胞白血病患者的 CCL17/CCL22-CCR4 轴进行评估。

目的：急性淋巴细胞白血病（ALL）是最常见的儿科癌症。趋化因子通过招募白细胞和调节疾病严重程度在白血病过程中发挥着不同的作用。鉴于趋化因子/受体轴的突出作用，本研究旨在测量B细胞ALL（B-ALL）患儿血液中CCR4及其配体的表达水平。我们还评估了细胞毒性化疗对该轴的影响：研究纳入了 30 名 B-ALL 患儿，并在化疗疗程结束后进行了为期 30 天的随访。血液采样在化疗前后进行。30 名健康捐献者也作为对照组参与了研究。研究人员通过实时定量 PCR 检测了 CCL17、CCL22 和 CCR4 基因的 mRNA 表达。流式细胞术方法还评估了表达 CCR4 的外周血单核细胞（CCR4 + PBMCs）的频率。此外，我们还评估了CCL17/CCL22-CCR4轴与ALL患者的一些诊断、预后和预测性生物标志物之间的关联：结果：与健康对照组相比，CCL17/CCL22-CCR4轴与乳酸脱氢酶（LDH）在B-ALL儿科患者中存在过表达。诱导化疗后，CCL17/CCL22-CCR4 轴的血液表达水平已达到健康对照组的水平。结论：CCL17/CCL22-CCR4轴的血液表达水平在诱导化疗后达到了健康对照组的水平：结论：CCL17/CCL22-CCR4 轴可用作 B-ALL 的新型预测和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.